DE60222790D1 - Dendrimere zur verwendung in gezielter verabreichung - Google Patents

Dendrimere zur verwendung in gezielter verabreichung

Info

Publication number
DE60222790D1
DE60222790D1 DE60222790T DE60222790T DE60222790D1 DE 60222790 D1 DE60222790 D1 DE 60222790D1 DE 60222790 T DE60222790 T DE 60222790T DE 60222790 T DE60222790 T DE 60222790T DE 60222790 D1 DE60222790 D1 DE 60222790D1
Authority
DE
Germany
Prior art keywords
dendrimers
targeted administration
bioactive molecules
molecules
spleen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222790T
Other languages
English (en)
Other versions
DE60222790T2 (de
Inventor
Ijeoma Florence Uchegbu
Avril Munro
Andreas Gerhart Schatzlein
Alexander Irvine Gray
Bernd Zinselmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Pharmacy University of London
Original Assignee
University of Glasgow
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, University of Strathclyde filed Critical University of Glasgow
Application granted granted Critical
Publication of DE60222790D1 publication Critical patent/DE60222790D1/de
Publication of DE60222790T2 publication Critical patent/DE60222790T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/005—Dendritic macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60222790T 2001-10-19 2002-10-17 Dendrimere zur verwendung in gezielter verabreichung Expired - Lifetime DE60222790T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0125216.2A GB0125216D0 (en) 2001-10-19 2001-10-19 Dendrimers for use in targeted delivery
GB0125216 2001-10-19
PCT/GB2002/004706 WO2003033027A2 (en) 2001-10-19 2002-10-17 Dendrimers for use in targeted delivery

Publications (2)

Publication Number Publication Date
DE60222790D1 true DE60222790D1 (de) 2007-11-15
DE60222790T2 DE60222790T2 (de) 2008-07-17

Family

ID=9924221

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222790T Expired - Lifetime DE60222790T2 (de) 2001-10-19 2002-10-17 Dendrimere zur verwendung in gezielter verabreichung

Country Status (8)

Country Link
US (1) US20050019923A1 (de)
EP (1) EP1436011B1 (de)
JP (1) JP2005511533A (de)
AT (1) ATE374625T1 (de)
CA (1) CA2463974C (de)
DE (1) DE60222790T2 (de)
GB (1) GB0125216D0 (de)
WO (1) WO2003033027A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946772B (zh) * 2004-04-20 2013-01-02 德瑞迪克纳米科技公司 具有增强的扩增性和内部官能度的树枝状聚合物
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
MX2007010402A (es) * 2005-04-20 2008-01-22 Dendritic Nanotechnologies Inc Polimeros dendriticos con amplificacion mejorada y funcionalidad interior.
AU2006268736B2 (en) * 2005-07-08 2011-12-22 Janssen Pharmaceutica N.V. Modified poly(propylene-imine) dendrimers and their use as transfection agents for anionic bioactive factors
ES2265291B1 (es) * 2005-07-22 2008-03-01 Universidad De Alcala Nuevos dendrimeros carbosilanos, su preparacion y sus usos.
CA2622021C (en) 2005-09-14 2014-07-15 Wisconsin Alumni Research Foundation Composition comprising a dendrimer and the use thereof for binding phosphate
US8114393B2 (en) * 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
CA2627459C (en) * 2005-10-25 2011-08-09 Evonik Degussa Gmbh Preparations containing hyperbranched polymers
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
BRPI0715053A2 (pt) * 2006-07-18 2013-03-19 Genzyme Corp composiÇço farmacÊutica, mÉtodo para tratar doenÇas, e, polÍmero
US20100004124A1 (en) * 2006-12-05 2010-01-07 David Taft Systems and methods for delivery of materials for agriculture and aquaculture
EP2500015A1 (de) * 2006-12-05 2012-09-19 Landec Corporation Verabreichung von Arzneimitteln
US20090263346A1 (en) * 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
US8399007B2 (en) * 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP1982698A1 (de) * 2007-04-18 2008-10-22 Evonik Degussa GmbH Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen
US8678686B2 (en) * 2007-05-01 2014-03-25 Pgr-Solutions Multi-chain lipophilic polyamines
US8114883B2 (en) * 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
DE102008000290A1 (de) 2008-02-13 2009-08-20 Evonik Degussa Gmbh Lagerstabile Produktsyteme für Prämixformulierungen
DE102008042923A1 (de) 2008-10-17 2010-04-22 Evonik Goldschmidt Gmbh Präparate zur gesteuerten Freisetzung von Wirkstoffen
GB0903559D0 (en) 2009-03-02 2009-04-08 Univ London Pharmacy Oral delivery of hydrophilic drugs to the brain
DE102009028255A1 (de) 2009-08-05 2011-02-10 Evonik Degussa Gmbh Mikrostrukturierte multifunktionale anorganische Coating-Additive zur Vermeidung von Fouling (Biofilmbewuchs) bei aquatischen Anwendungen
US9623046B2 (en) 2009-08-06 2017-04-18 The Trustees Of The University Of Pennsylvania Amphiphilic Janus-dendrimers
DE102009036767A1 (de) 2009-08-08 2011-02-10 Evonik Degussa Gmbh Kompositpartikel für den Einsatz in der Mundhygiene
GB0918822D0 (en) 2009-10-27 2009-12-09 Univ Strathclyde Targeted dendrimers
US8226985B2 (en) * 2010-01-28 2012-07-24 International Business Machines Corporation Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery
WO2012090223A1 (en) * 2010-12-29 2012-07-05 Indian Institute Of Science Poly(ether imine) dendrimers and uses thereof
US9943608B2 (en) 2012-11-13 2018-04-17 Baylor College Of Medicine Multi-arm biodegradable polymers for nucleic acid delivery
CN110872583A (zh) 2012-12-12 2020-03-10 布罗德研究所有限公司 用于序列操纵和治疗应用的系统、方法和组合物的递送、工程化和优化
SG11201510286QA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
KR20160030187A (ko) 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
JP2017527256A (ja) 2013-12-12 2017-09-21 ザ・ブロード・インスティテュート・インコーポレイテッド ＨＢＶ及びウイルス性疾患及び障害のためのＣＲＩＳＰＲ−Ｃａｓ系及び組成物の送達、使用及び治療適用
MX2016007327A (es) 2013-12-12 2017-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
EP3080271B1 (de) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systeme, verfahren und zusammensetzungen zur sequenzmanipulation mit optimierten funktionellen crispr-cas-systemen
MX2016007328A (es) 2013-12-12 2017-07-19 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
CA2932472A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3080259B1 (de) 2013-12-12 2023-02-01 The Broad Institute, Inc. Konstruktion von systemen, verfahren und optimierte führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3985115A1 (de) 2014-12-12 2022-04-20 The Broad Institute, Inc. Geschützte guide-rnas (pgrnas)
EP3230452A1 (de) 2014-12-12 2017-10-18 The Broad Institute Inc. Totführungen für crispr-transkriptionsfaktoren
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3234192B1 (de) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbeeinflusste identifizierung von doppelstrangbrüchen und genomischer umordnung durch genomweite einsatzerfassungssequenzierung
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
IL293323B2 (en) 2015-06-18 2024-01-01 Massachusetts Inst Technology CRISPR enzyme mutations that reduce unintended effects
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
EP3666895A1 (de) 2015-06-18 2020-06-17 The Broad Institute, Inc. Neuartige crispr-enzyme und systeme
AU2016308339A1 (en) 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3365441A1 (de) 2015-10-22 2018-08-29 The Broad Institute Inc. Crispr-enzyme des typs vi-b und systeme
EP3368687B1 (de) 2015-10-27 2021-09-29 The Broad Institute, Inc. Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368689B1 (de) 2015-10-28 2020-06-17 The Broad Institute, Inc. Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
EP3445856A1 (de) 2016-04-19 2019-02-27 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
SG11201810179RA (en) 2016-04-19 2018-12-28 Broad Inst Inc Novel crispr enzymes and systems
CA3026112A1 (en) 2016-04-19 2017-10-26 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
US11779657B2 (en) 2016-06-10 2023-10-10 City Of Hope Compositions and methods for mitochondrial genome editing
EP3455357A1 (de) 2016-06-17 2019-03-20 The Broad Institute Inc. Typ-vi-crispr-orthologe und systeme
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11739308B2 (en) 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
US11840711B2 (en) 2017-04-12 2023-12-12 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3692152A4 (de) 2017-10-04 2021-12-01 The Broad Institute, Inc. Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
AU2019318079A1 (en) 2018-08-07 2021-01-28 Massachusetts Institute Of Technology Novel Cas12b enzymes and systems
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
WO2021146625A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
CN112439074B (zh) * 2020-12-03 2022-09-13 浙江大学 可快速提高功能多肽亲和力的偶联物及其制备方法和应用
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
MX9504664A (es) * 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
DE10016881B4 (de) * 2000-04-05 2006-06-01 Qiagen Gmbh Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer
US20050019267A1 (en) * 2001-06-25 2005-01-27 Brechbiel Martin W Macromolecular imaging agents for liver imaging

Also Published As

Publication number Publication date
CA2463974A1 (en) 2003-04-24
WO2003033027A3 (en) 2003-09-12
WO2003033027A2 (en) 2003-04-24
JP2005511533A (ja) 2005-04-28
DE60222790T2 (de) 2008-07-17
US20050019923A1 (en) 2005-01-27
EP1436011A2 (de) 2004-07-14
ATE374625T1 (de) 2007-10-15
CA2463974C (en) 2012-01-03
GB0125216D0 (en) 2001-12-12
EP1436011B1 (de) 2007-10-03

Similar Documents

Publication Publication Date Title
ATE374625T1 (de) Dendrimere zur verwendung in gezielter verabreichung
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
ATE465255T1 (de) Verabreichung von sirnas
WO2006007712A8 (en) Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
EP1414471A4 (de) Therapeutische mittel mit pro-apoptotischen proteinen
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2007022239A3 (en) Pharmaceutical formulations for sustained drug delivery
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
NO20055209L (no) Peptabody for cancerbehandling
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
SI2157192T1 (sl) Sestavki za diagnozo in terapijo bolezni, povezanih z aberantno ekspresijo Futrinov (R-Spondinov)
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO2005026205A3 (de) Differentiell in tumoren exprimierte genprodukte und deren verwendung
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SCHOOL OF PHARMACY, UNIVERSITY OF LONDON, LOND, GB